-
Did you know that TherapeutAix offer a project management service?
In this role, we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely…
-
New Innovative Partnerships?
Last year, Darcey Black, Director of Translational Science at TherapeutAix, together with colleagues, Gregor MacDonald from Lundbeck and Mo Alavijeh…
-
2022: A TherapeutAix Roundup
As the year draws to a close, we wanted to take a look back at our activities throughout 2022, reflecting…
-
What’s it like to work with us?
What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our…
-
One Project, Many Customers
In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets…
-
The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services…
-
Reflections from ECM2022, Copenhagen, July 2022
The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of…
-
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach…
-
Rare and common diseases – where’s the link?
It’s Rare Disease Day. Last year on our blog, we looked at how rare diseases can help better our understanding…
-
Adoption and cost-effectiveness of IPF therapies
Fibrotic remodelling occurs in many diseases. Thinking about idiopathic pulmonary fibrosis (IPF) as a ‘purely’ fibrotic condition, with currently unknown…
